EP4247347A4 - Targeted nanoparticles carrying dual drugs in the treatment of melanoma - Google Patents

Targeted nanoparticles carrying dual drugs in the treatment of melanoma Download PDF

Info

Publication number
EP4247347A4
EP4247347A4 EP21898836.8A EP21898836A EP4247347A4 EP 4247347 A4 EP4247347 A4 EP 4247347A4 EP 21898836 A EP21898836 A EP 21898836A EP 4247347 A4 EP4247347 A4 EP 4247347A4
Authority
EP
European Patent Office
Prior art keywords
melanoma
treatment
targeted nanoparticles
nanoparticles carrying
carrying dual
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP21898836.8A
Other languages
German (de)
French (fr)
Other versions
EP4247347A1 (en
Inventor
Güliz AK DEMIROZ
Senay SANLIER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ege Universitesi
Original Assignee
Ege Universitesi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ege Universitesi filed Critical Ege Universitesi
Publication of EP4247347A1 publication Critical patent/EP4247347A1/en
Publication of EP4247347A4 publication Critical patent/EP4247347A4/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5176—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP21898836.8A 2020-11-30 2021-11-05 Targeted nanoparticles carrying dual drugs in the treatment of melanoma Pending EP4247347A4 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
TR202019315 2020-11-30
TR202115623 2021-10-07
PCT/TR2021/051146 WO2022115075A1 (en) 2020-11-30 2021-11-05 Targeted nanoparticles carrying dual drugs in the treatment of melanoma

Publications (2)

Publication Number Publication Date
EP4247347A1 EP4247347A1 (en) 2023-09-27
EP4247347A4 true EP4247347A4 (en) 2024-05-22

Family

ID=81754706

Family Applications (1)

Application Number Title Priority Date Filing Date
EP21898836.8A Pending EP4247347A4 (en) 2020-11-30 2021-11-05 Targeted nanoparticles carrying dual drugs in the treatment of melanoma

Country Status (2)

Country Link
EP (1) EP4247347A4 (en)
WO (1) WO2022115075A1 (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013056132A2 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US20130315831A1 (en) * 2010-09-03 2013-11-28 Massachusetts Institute Of Technology Lipid-polymer hybrid particles
US20190160015A1 (en) * 2016-01-08 2019-05-30 The Regents Of The University Of California Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery
CN110433292A (en) * 2019-09-06 2019-11-12 沈阳药科大学 A kind of double targeting materials and its application in drug delivery

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2882706A1 (en) * 2012-08-13 2015-06-17 Massachusetts Institute of Technology Amine-containing lipidoids and uses thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130315831A1 (en) * 2010-09-03 2013-11-28 Massachusetts Institute Of Technology Lipid-polymer hybrid particles
WO2013056132A2 (en) * 2011-10-14 2013-04-18 Stc.Unm Porous nanoparticle-supported lipid bilayers (protocells) for targeted delivery including transdermal delivery of cargo and methods thereof
US20190160015A1 (en) * 2016-01-08 2019-05-30 The Regents Of The University Of California Mesoporous silica nanoparticles with a lipid bilayer coating for cargo delivery
CN110433292A (en) * 2019-09-06 2019-11-12 沈阳药科大学 A kind of double targeting materials and its application in drug delivery

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
MORAES S ET AL: "Targeted nanostructured lipid carriers for doxorubicin oral delivery", INTERNATIONAL JOURNAL OF PHARMACEUTICS, ELSEVIER, NL, vol. 592, 30 October 2020 (2020-10-30), XP086418542, ISSN: 0378-5173, [retrieved on 20201030], DOI: 10.1016/J.IJPHARM.2020.120029 *
See also references of WO2022115075A1 *

Also Published As

Publication number Publication date
EP4247347A1 (en) 2023-09-27
WO2022115075A1 (en) 2022-06-02

Similar Documents

Publication Publication Date Title
EP3684353A4 (en) Topical formulations of cannabinoids and use thereof in the treatment of pain
EP3325473A4 (en) Compounds and uses thereof in the treatment of cancers and other medical conditions
WO2016207090A3 (en) Targeted conjugates of ksp inhibitors
WO2012009288A9 (en) Administration of hypoxia activated prodrugs and antiangiogenic agents for the treatment of cancer
HK1170485A1 (en) 1,2,4-thiazolidin-3-one derivatives and their use in the treatment of cancer 124--3-
WO2009009587A3 (en) Apoptosis-modulating protein therapy for proliferative disorders and nanoparticles containing the same
WO2009140675A3 (en) Combination therapy with pm00104 and another antitumor agent
EP3565607A4 (en) Fusogenic lipid nanoparticles and methods for manufacturing and use for therapeutic protein production and for treatment
WO2012061390A3 (en) Therapeutic compositions and methods
EP3402527A4 (en) Therapeutic nanoparticles for the treatment of neuroblastoma and other cancers
WO2018102261A3 (en) Boronic derivatives hydroxamates as anticancer agents
EP3773623A4 (en) Trans-antigen targeting in heterogeneous cancers and methods of use thereof
EP3565553A4 (en) Intratumoral administration of sirolimus for treatment of prostate cancer
EP3937980A4 (en) Modified micrornas and their use in the treatment of cancer
EP3347010A4 (en) Synthesis and composition of photodynamic therapeutic agents for the targeted treatment of cancer
EP3703757A4 (en) Anti-tissue factor antibody-drug conjugates and their use in the treatment of cancer
EP3604529A4 (en) Microrna and uses thereof in prevention and/or treatment of fibroplasia medical sign and/or syndrome
EP4099988A4 (en) Rna-loaded nanoparticles and use thereof for the treatment of cancer
WO2011130692A3 (en) Androgen induced oxidative stress inhibitors
WO2007128588A3 (en) Glutadon
EP3700528A4 (en) Methods and compositions for maintaining opioid efficacy in the treatment of pain
EP4247347A4 (en) Targeted nanoparticles carrying dual drugs in the treatment of melanoma
TWI799923B (en) Use of thioimidazolidinone drugs in the treatment of covid-19 disease
GB202317288D0 (en) Pyrrolopyridone derivatives useful in the treatment of cancer
IL308058A (en) Molephantin derivatives useful in the treatment of cancer

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20230623

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009510000

Ipc: A61K0047690000

A4 Supplementary search report drawn up and despatched

Effective date: 20240423

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 35/00 20060101ALI20240417BHEP

Ipc: A61K 9/51 20060101ALI20240417BHEP

Ipc: A61K 47/69 20170101AFI20240417BHEP